The Uromigos strives to provide balanced, scientific content related to care of patients with GU malignancies. Click the link below to listen to our podcasts.
Can patients with muscle-invasive bladder cancer avoid radical cystectomy?
From radical cystectomy to bladder-sparing approaches, the debate took center stage at #UromigosLive in Nashville 🎸
Listen to the full discussion ⬇️
🎧 Apple: apple.co/4t9r8Ps
🎧 Spotify: bit.ly/4iPpf6Q
How much should ctDNA and utDNA influence treatment decisions in muscle-invasive bladder cancer?
From risk assessment to treatment selection, our expert panel explores the evolving role of biomarkers 👀
Listen to the full discussion, recorded live at #UromigosLive in Nashville ⬇️
🎧 Apple: apple.co/4f9n0sM
🎧 Spotify: bit.ly/4kkYfxl
That’s a wrap on Uromigos Live in Nashville! The weekend was packed with lively debates, insightful conversations, and a little friendly competition at The Uromigos Live World Cup.
Looking for Spanish-language coverage of the weekend? You’ll find it all on @LosUromigos 🎙️
EV + pembrolizumab vs. EV + durvalumab.
How does the VOLGA trial impact treatment decisions in muscle-invasive bladder cancer?
Listen to the full debate, recorded live at #UromigosLive in Nashville 🎸
🎧 Spotify: bit.ly/4kkdcQc
🎧 Apply: apple.co/48Gvvbn
The OncoAlert 🚨Coverage of #UromigosLive 🎸
VOLGA: Do We Need Adjuvant EV?
KEYNOTE-905 and KEYNOTE-B15 showed that perioperative EV-pembro works in MIBC. But both trials gave EV before and after surgery. Does every patient need both?
Dr. Matthew Galsky🇺🇸 (@MattGalsky from Mount Sinai) and and Dr. Jonathan Rosenberg🇺🇸 @DrRosenbergMSK
from @MSKCancerCenter break down VOLGA:
▪️ Cisplatin-ineligible MIBC
▪️ 3 cycles of EV + durvalumab → cystectomy → adjuvant durvalumab only (no adjuvant EV)
▪️ Significant benefit vs cystectomy alone. The regimen was FDA approved the day of the session
▪️ The tremelimumab arm improved EFS but not OS, and wasn’t approved
🔍 Compared with EV-pembro, the confidence intervals overlap across the major endpoints, though EV-pembro’s point estimates are slightly lower.
📌 His framing: there are now two approaches, EV before and after surgery, or EV before surgery only. The open question is who needs more and who needs less, and ctDNA plus pathologic stage may help answer it. VOLGA’s post-op ctDNA data is expected at an upcoming meeting.
👇 Watch the full conversation
#BladderCancer#MIBC#GUOnc#OncoAlert@uromigos@Uromigos, @tompowles1, @brian_rini, @shilpaonc, @montypal, @TiansterZhang, @neerajaiims, @katy_beckermann, @PGrivasMDPhD, @TwoOncDocs, @DrKarineTawagi, @nataliagandur, @Dr_Aggen, @AmandaNizamMD, @scocmem, @lalaniMD, @NazliDizman, @weoncologists, @LosUromigos, @uromigosjapan
Is platinum chemotherapy entering a new era in muscle-invasive bladder cancer?
Recorded live at #UromigosLive in Nashville, our expert panel revisited 15 years of clinical trials, debated the evolving role of chemotherapy and immunotherapy, and explored what's next for MIBC treatment 🎸
Listen to the full discussion 🎧
Spotify: bit.ly/4iKPSKj
Apple: apple.co/4t59350
Rounding up #UromigosLive . Thanks to everyone that participated.
👉Monty Pal @montypal is leading the TCE drive to potently transforming RCC. He’s running for the ASCO board too and get our vote every time. Vote soon !!! @OncoAlert@DrChoueiri@neerajaiims
Bladder cancer ph2 trial concept ADAPT-MIBC @SuzanneColeMD@PGrivasMDPhD
👥 pts ctDNA+ after EV/IO & switch therapies BEFORE cystectomy or chemo-RT OR observation until they are (-)
➡️ goal to avoid interruption in systemic therapy for ctDNA+ pts
#UromigosLive@OncoAlert
Ivonescimab (with chemo) has been rejected by FDA in EGFRm TKI refractory lung cancer. The trial achieved impressive PFS but not OS (with some subgroup inconsistency). We see PFS achieve approvals without OS in other tumours including all 3 GU cancers. It’s not always easy to predict the future in terms of results or regulatory approvals, but the class of drug seems broadly active. VEFF/PD1s are in R3 trials in bladder cancer with EV. @OncoAlertgoogle.com/goto?url=CAESwgEB…
Thoughtful debate and banter on the latest in GU cancers for @uromigos. Palpable excitement on how far we’ve come in GU cancers. The livestream is available — Tune in wherever you are!
Brilliant summary from @tompowles1 & @brian_rini ahead of @Uromigos. Really looking fwd to discussing the data on Saturday at #UromigosLive 2026. As Brian points out, response rates are high with #XMab819 in a heavily refractory population of patients - 45% in those who have received prior checkpoint at at least 2 VEGF-TKIs in one of our analyses. Agree that we need to brainstorm ways to move these strategies ahead quickly for our #kidneycancer patients.